SND 209
Alternative Names: SND-209Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Floratek Pharma
- Class Antineoplastics; Polyphenols; Small molecules
- Mechanism of Action Matrix metalloproteinase 9 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Ovarian cancer
Most Recent Events
- 19 Dec 2024 Preclinical trials in Ovarian cancer in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)
- 19 Dec 2024 Preclinical trials in Breast cancer in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)